Skip to Content

Sotalol Pregnancy and Breastfeeding Warnings

Sotalol is also known as: Betapace, Betapace AF, Sorine, Sotalol Hydrochloride AF, Sotylize

Sotalol Pregnancy Warnings

Benefit should outweigh risk. AU TGA pregnancy category: C US FDA pregnancy category: B Comments: -This drug should be used during late pregnancy only if the potential benefit outweighs the potential risk to the fetus. -Beta-blockers may cause decreased placental perfusion (resulting in fetal death and premature birth), fetal and neonatal bradycardia, and hypoglycemia. This drug should be discontinued 2 to 3 days before the expected delivery date, if possible, to avoid increased uterine contractility and effects of beta blockade in the neonate.

-Animal studies have failed to reveal evidence of teratogenicity, but have revealed a slight increase in fetal death likely to be due to maternal toxicity at 16 times the maximum recommended human dose (on a mg/kg basis), and increased fetal absorptions at 100 times the maximum recommended human dose (on a mg/kg basis). There are no controlled data in human pregnancy. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Sotalol Breastfeeding Warnings

A decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Yes Comments: -Other beta-adrenergic blocking drugs are preferred to this drug, especially while nursing a newborn or preterm infant, because of its extensive excretion into breastmilk, its renal excretion, and minimal safety data in breastfed infants. -Adverse effects in the infant are possible.

See references

References for pregnancy information

  1. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL:" ([2006]):

References for breastfeeding information

  1. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL:" ([2006]):
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.